| Financier | Commitments |
|---|---|
| IDA Credit | 200.00 |
NG-Polio Eradication Support - Additional Financing
Development Objective
To assist the Recipient, as part of a global polio eradication effort, to achieve and sustain at least 80% coverage with oral polio vaccine immunization in every state in the Recipient's territory, and sustain national routine immunization coverage.
Key Details
Project Details
P154660
Closed
Ayodeji Odutolu , Ana Besarabic, Shunsuke Mabuchi
N/A
March 16, 2015
(as of board presentation)
April 10, 2015
N/A
US$ 200.00 million
N/A
2015
US$ 200.00 million
C
March 27, 2024
April 30, 2021
No
BANK APPROVED
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | N/A |
| IDA Commitment | 200.00 |
| IBRD + IDA Commitment | 200.00 |
| Lending Instrument | |
|---|---|
| Grant Amount | N/A |
| Total Project Cost** | 200.00 |
Summary Status of World Bank Financing (US$ Millions) as of February 28, 2025
No data available.
Detailed Financial Activity as of February 28, 2025
No data available.
Results Framework
PROJECT DEVELOPMENT OBJECTIVE INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Immunization coverage of OPV in the country Value 91.80 97.00 80.00 Date April 15, 2012 September 30, 2014 July 31, 2015 Comment Source: Enhanced Independent Monitoring (EIM) data Average of High Risk LGAs in 13 Northern statesSource: Enhanced Independent Monitoring (EIM) data. End-of-project target issurpassed. To be verified through independent performance audit at the end of the project. Immunization coverage of OPV in each high risk state Value 89.00 0.00 80.00 Date December 31, 2012 October 29, 2014 July 31, 2015 Comment Kaduna: 84%Sokoto: 84%Zamfara: 84%Katsina: 88% Bauchi: 91%Kano: 91%Jigawa: 93%Niger: 95%Source: Independent PerformanceAudit No performance audit has been implemented and state level estimate is not available. The proposed independent performance audit(for buy-down decision) is before the project closure in July 2015.Percentage of high risk LGAs that achieved 80% OPV coverageincreased from 53% in October 2012 (the time of previous performance audit) to 86% in March 2014, which is the highest in history.This suggest higher OPV coverage at state level than previous audit results (89%) in Oct/Dec 2012 To be verified through independent performance audit at the end of the project. Children immunized (number) Value 0.00 27913940.00 6561446.00 Date July 9, 2012 September 30, 2014 December 31, 2014 Comment Source: WHO, UNICEF campaign reports Source: WHO, UNICEF campaign reports(Changed from cumulative to average of each SIPD immunization during the ISR period from thisISR, for comparison with End Target) Target tentative (varies by the situation of epidemic) Direct project beneficiaries Value 0.00 27913940.00 6561446.00 Date July 9, 2012 September 30, 2014 December 31, 2014 Comment Source: WHO, UNICEF campaign reports Source: WHO, UNICEF campaign reports(Changed from cumulative to average of each SIPD immunization during the ISR period from thisISR, for comparison with End Target) Target tentative (varies by the situation of epidemic) Children immunized - under 12 months against DTP3 (number) Value 0.00 10552219.00 6561446.00 Date July 9, 2012 September 30, 2014 December 31, 2014 Comment Source: WHO, UNICEF campaign reports Source: WHO, UNICEF campaign reports(Cumulative) Target tentative (varies by the situation of epidemic) Female beneficiaries Value 0.00 50.00 50.00 Date July 9, 2012 September 30, 2014 December 31, 2014 Comment
INTERMEDIATE RESULTS INDICATORS
| INDICATOR | BASELINE | CURRENT | TARGET |
|---|
Percentage of teams with viable vaccine according to the Vaccine Vial Monitor Value 97.00 97.00 98.00 Date April 15, 2012 September 30, 2014 December 31, 2014 Comment Source: Vaccine Vial Monitor Average of Nov 2013 - Sep 2014 rounds.Source: Vaccine Vial Monitor Percentage of campaigns where vaccines are available on time Value 100.00 100.00 100.00 Date July 9, 2012 September 30, 2014 December 31, 2014 Comment Source: WHO/UNICEF campaign reports Source: WHO/UNICEF campaign reportsTarget reached. Pentavalent 3 coverage rate Value 52.00 52.00 52.00 Date May 5, 2014 February 25, 2015 May 31, 2017 Comment Source: SMART Survey (NBS/UNICEF) Source: SMART Survey (NBS/UNICEF) Source: SMART Survey (NBS/UNICEF)